trending Market Intelligence /marketintelligence/en/news-insights/trending/kJe84Ajrd6Eh4RPvMtsskg2 content esgSubNav
In This List

Bristol-Myers' Opdivo meets endpoint in gastric cancer study

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Bristol-Myers' Opdivo meets endpoint in gastric cancer study

Bristol-Myers Squibb Co.'s Opdivo achieved the desired efficacy and safety benchmarks in a phase 3 clinical trial involving patients with advanced gastric cancer who become intolerant to chemotherapy.

The drug significantly reduced the risk of death by 37% in patients suffering from the cancer when compared to placebo.

Opdivo was co-developed by Bristol-Myers and Ono Pharmaceutical Co. Ltd., and is already approved for the treatment of unresectable or metastatic melanoma, either as a single agent or in combination with Yervoy.